Flaharty Asset Management LLC Makes New $94,000 Investment in Zimmer Biomet Holdings, Inc. $ZBH

Flaharty Asset Management LLC purchased a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 1st quarter, according to its most recent filing with the SEC. The fund purchased 831 shares of the medical equipment provider’s stock, valued at approximately $94,000.

Several other hedge funds have also made changes to their positions in the business. Garde Capital Inc. purchased a new stake in shares of Zimmer Biomet in the first quarter valued at $29,000. Washington Trust Advisors Inc. acquired a new stake in Zimmer Biomet in the 1st quarter worth about $30,000. Columbia River Financial Group LLC acquired a new position in shares of Zimmer Biomet during the 1st quarter valued at about $30,000. Menard Financial Group LLC purchased a new position in shares of Zimmer Biomet during the 4th quarter worth about $30,000. Finally, Accent Capital Management LLC purchased a new position in shares of Zimmer Biomet during the 1st quarter worth about $35,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of the company’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the completion of the transaction, the senior vice president directly owned 6,833 shares in the company, valued at approximately $711,656.95. This represents a 18.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.39% of the company’s stock.

Zimmer Biomet Stock Down 1.5%

Shares of NYSE ZBH opened at $102.33 on Thursday. The stock has a fifty day moving average price of $99.06 and a 200 day moving average price of $99.63. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.22 and a 12-month high of $114.72. The company has a market cap of $20.27 billion, a P/E ratio of 24.90, a P/E/G ratio of 2.05 and a beta of 0.68.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.98 by $0.09. The company had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company’s revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a dividend of $0.24 per share. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.36%.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of recent analyst reports. Roth Capital restated a “buy” rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Raymond James Financial boosted their price objective on shares of Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. UBS Group increased their target price on Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a research report on Friday, August 8th. Royal Bank Of Canada boosted their price target on Zimmer Biomet from $112.00 to $115.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Finally, Evercore ISI dropped their price target on Zimmer Biomet from $102.00 to $96.00 and set an “in-line” rating for the company in a research note on Tuesday, July 8th. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $111.00.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.